Fennec Pharma Stock Plunges On Expected FDA CRL For Pedmark For Chemo-Induced Hearing Issues

Fennec Pharmaceuticals Inc FENC said it expects to receive a Complete Response Letter (CRL) from the FDA regarding its marketing application for Pedmark.

  • Related Link: Fennec Pharma Stock Is Trading Higher As Pedmark Is Under FDA Review For Chemo-Induced Toxicity.
  • The FDA has indicated that, following a recent inspection of the manufacturing facility of the drug product manufacturer, deficiencies have been identified. 
  • Pedmark is under review for intravenous administration to prevent ototoxicity associated with cisplatin chemotherapy in pediatric patients over 1 month to 18 years of age with localized, non-metastatic, solid tumors.
  • Once the official CRL is received, the company plans to request a Type A meeting to discuss the deficiencies and steps required for the resubmission.
  • The marketing authorization for sodium thiosulfate (tradename Pedmarqsi) is currently under evaluation in Europe. 
  • Pedmark received Breakthrough Therapy and Fast Track Designation by the FDA in March 2018. 
  • See here Benzinga's Full FDA Calendar.
  • Price Action: FENC shares are down 49.7% at $4.85 during the premarket session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsShort IdeasHealth CareFDAMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!